Mirna Therapeutics
- Company typePrivate
- Founded2007
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Mirna Therapeutics firmographics
Firmographics- Name
- Mirna Therapeutics
- Website
- https://mirnatherapeutics.com
- Company type
- Private
- Founded year
- 2007
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mirna Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industries
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)
Keywords
Where Mirna Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Markets served
Mirna Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Mirna Therapeutics product offering
Product offeringCore offering
Mirna Therapeutics is a clinical-stage biotechnology company that researches and develops microRNA (miRNA)-directed human oncology therapies. The company's pipeline focuses on leveraging tumor-suppressor and oncogenic miRNA biology to create novel cancer treatment candidates, advancing candidates from discovery through preclinical and clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- miRNA-directed oncology therapeutics pipeline
Companies that use Mirna Therapeutics
Customer profileIdeal customer profiles1 record
Mirna Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mirna Therapeutics competitors and assessment
Company assessmentBroad incumbents
- BioNTech: BioNTech develops mRNA-based immunotherapies and oncology vaccines. It operates in the RNA therapeutics space with a parallel oncology focus, making it a broad incumbent peer for benchmarking RNA-platform companies.
- Moderna: Moderna is the leading mRNA therapeutics company with oncology programs. While mRNA is mechanistically distinct from miRNA, both are RNA-therapeutics platforms addressing cancer, making Moderna a broad incumbent peer in the RNA-oncology category.
- Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, addressing similar gene-expression modulation in oncology and rare disease. It is a broader incumbent in the oligonucleotide therapeutics space that overlaps with Mirna's RNA-modality approach.
- Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage RNAi (siRNA) therapeutics company, working through the same RISC-mediated gene-silencing pathway that microRNA therapeutics exploit. It anchors the small-RNA therapeutic space that Mirna operates in.
Direct peers
- Regulus Therapeutics: Regulus was the most direct microRNA therapeutics peer, developing anti-miR and miR mimics in oncology and rare disease. It shares Mirna's miRNA mechanism of action and clinical-stage oncology focus, making it the closest historical comparable.
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using targeted delivery systems (e.g., TRiM platform) for oncology and other indications. It is a direct small-RNA therapeutics peer working through gene-silencing mechanisms analogous to Mirna's miRNA approach.
- Dicerna Pharmaceuticals: Dicerna developed GalNAc-conjugated RNAi (siRNA) therapeutics with a similar focus on liver and oncology indications. It is directly comparable as a small-RNA gene-silencing platform that was ultimately acquired by Novo Nordisk.
- miRagen Therapeutics (now Viridian Therapeutics): miRagen was a clinical-stage microRNA-targeted therapeutics company focused on hematological and oncology indications. It was the most directly comparable miRNA-focused peer to Mirna Therapeutics and was acquired and renamed Viridian Therapeutics.
Emerging players
- Arcturus Therapeutics: Arcturus develops RNA-based therapeutics, including self-amplifying mRNA and RNAi approaches, with both rare-disease and oncology programs. It is an emerging player in the broader RNA therapeutics category with partial mechanistic overlap to Mirna.
- EnGeneIC: EnGeneIC is a clinical-stage oncology biotech developing targeted nanocell-based RNAi delivery platforms for solid tumors. It represents an emerging delivery-enabled RNA therapeutics approach relevant to Mirna's miRNA oncology pipeline.
Market position
Customer concentration
Mirna Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirna Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Mirna Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirna Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirna Therapeutics
What does Mirna Therapeutics do?
Mirna Therapeutics is a clinical-stage biotechnology company that researches and develops microRNA (miRNA)-directed human oncology therapies. The company's pipeline focuses on leveraging tumor-suppressor and oncogenic miRNA biology to create novel cancer treatment candidates, advancing candidates from discovery through preclinical and clinical development.
When was Mirna Therapeutics founded?
Mirna Therapeutics was founded in 2007. It employs 11 to 50 people.
Where is Mirna Therapeutics based?
Mirna Therapeutics is headquartered in Austin, United States, in the North America region.
Who are Mirna Therapeutics's main competitors?
Broad incumbents on record are BioNTech, Moderna, Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Direct peers are Regulus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals and miRagen Therapeutics (now Viridian Therapeutics). Emerging players are Arcturus Therapeutics and EnGeneIC.
Does Mirna Therapeutics have an API?
No public API is recorded for Mirna Therapeutics.
What industry is Mirna Therapeutics in?
Mirna Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714.